Dermata Therapeutics, Inc. (DRMA)

US — Healthcare Sector
Peers: ZURA  PHIO  SONN  ATNF  CDIO  WINT  ENSC  PBLA  BXRX  ZVSA  REVB  NAVB  CYTO  IMMX  HEPA  AVRO  EFTR 

Automate Your Wheel Strategy on DRMA

With Tiblio's Option Bot, you can configure your own wheel strategy including DRMA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol DRMA
  • Rev/Share 0.0
  • Book/Share 1.4164
  • PB 0.5084
  • Debt/Equity 0.0
  • CurrentRatio 6.9657
  • ROIC -1.7908

 

  • MktCap 4592883.0
  • FreeCF/Share -2.0161
  • PFCF -0.4419
  • PE -0.324
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -2.7082

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 4
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints
DRMA
Published: March 27, 2025 by: PRNewsWire
Sentiment: Neutral

- XYNGARI™ achieved its primary endpoints, demonstrating highly statistically significant and clinically meaningful improvement in acne - - XYNGARI™ is the first once-weekly topical product candidate to demonstrate clinical benefit in a Phase 3 clinical trial for moderate-to-severe acne - - Over 30 million acne patients seek treatment in the U.S. each year - SAN DIEGO , March 26, 2025 /PRNewswire/ -- Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced positive topline results from the Company's first pivotal Phase 3 trial …

Read More
image for news BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis
DRMA
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral

- This would be Dermata's second patent for DMT410, if issued, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis - - The Company recently entered into a Clinical Trial Collaboration Agreement with Revance to study DMT410 for the treatment of axillary hyperhidrosis - - The Company also has an issued patent in Japan covering their DMT410 program for the treatment of hyperhidrosis - SAN DIEGO, CA / ACCESS Newswire / February 25, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and …

Read More
image for news Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

About Dermata Therapeutics, Inc. (DRMA)

  • IPO Date 2021-08-13
  • Website https://www.dermatarx.com
  • Industry Biotechnology
  • CEO Mr. Gerald T. Proehl
  • Employees 8

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.